[Potentiality of Immune Checkpoint Inhibitors for Advanced Esophageal and Gastric Cancer]

Area of Science:

• Oncology
• Immunology
• Pharmacology

Background:

• Immune checkpoint inhibitors (ICIs) represent a distinct therapeutic class from conventional cytotoxic and molecular targeting agents.
• ICIs are approved for malignant melanoma and non-small cell lung cancer in Japan.
• Their distinct mechanisms lead to unique anti-tumor effects and toxicity profiles.

Purpose of the Study:

• To review the distinct mechanisms, efficacy patterns, and toxicities of immune checkpoint inhibitors.
• To explore the emerging role of ICIs in gastrointestinal tract cancers.
• To highlight future research directions for optimizing ICI therapy.

Main Methods:

• Review of current literature and clinical trial data on immune checkpoint inhibitors.
• Comparative analysis of ICI mechanisms against conventional anti-neoplastic agents.
• Evaluation of ICI efficacy and toxicity in various cancer types, including gastrointestinal cancers.

Main Results:

• Immune checkpoint inhibitors demonstrate unique anti-tumor effects, including long-term survival and durable responses, despite potentially lower initial response rates.
• Distinct autoimmune-related toxicity profiles are characteristic of ICIs.
• Emerging clinical trial data suggests significant promise for ICIs in treating gastrointestinal tract cancers.

Conclusions:

• Immune checkpoint inhibitors offer a paradigm shift in cancer treatment with distinct efficacy and safety profiles.
• ICIs hold significant promise as future treatment options for gastrointestinal cancers.
• Further research into biomarkers and combination therapies is crucial for maximizing ICI benefits.